Patient Portal

Benjamin D. Schwartz, MD, PhD

Professor, Internal Medicine
Division of Rheumatology

Specialty Areas


Board Certifications

Allergy & Immunology
Internal Medicine

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Rheumatoid arthritis, osteoarthritis, lupus, arthritis, degenerative joint disease, spondyloarthropathy

  • Location(s)
  • Education
  • Publication & Research



Center for Advanced Medicine
Medicine Multispecialty Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 5
Office Phone: 314-286-2635
Fax: 314-884-6005



Medical Degree: Albert Einstein College Of Medicine, New York, New York 1972
Ph.D.: Albert Einstein College of Medicine, New York, New York 1971
B.A.: Columbia College, New York, New York 1965

Publication & Research

Publication & Research

Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch D, Buckwater J, Dougados M, Ehrlich G, Lequesne M, Lohmander S, Murphy W, Rosario-Jansen T, Schwartz B, Trippel S.  Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society.  Osteoarthritis Cartilage.  1996; 4:217-243. 

Schwartz BD
  Structure, function, and genetics of the HLA complex in rheumatic disease.  In: Koopman W (Ed) Arthritis and Allied Conditions, 13th Edition.  Williams and Wilkens, Baltimore, 1996, p. 545-564. 

Simon L, Lanza F, Lipsky P, Hubbard R, Talwaker S, Schwartz B, Isakson P, Geis G.  Preliminary study of the safety and efficacy of SC‑58635, A Novel Cyclooxygenase 2 Inhibitor.  Arthritis Rheum 1998; 41:1591-1602.

Schwartz BD.  The human leukocyte antigen complex.  In: Zvaifler N (Ed) Stein’s Internal Medicine 5th Edition. Mosby, St. Louis, 1998, p. 1115-1121.

Mengle-Gaw LJ, Schwartz BD.  Non-Steroidal Anti-Inflammatory Drugs.  In: Rich R, Fleisher TA, Shearer WT, Schroeder HW Jr., Kotzin B (Eds.) Clinical Immunology: Principles and Practice 2nd Edition.  Mosby International Limited, London, 2001, p. 107.1-107.10.


Mengle-Gaw LJ, Schwartz BD Cyclooxygenase-2 inhibitors: Promise or peril?  Mediators Inflamm.  2002; 11: 275-286.

Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA, and the Tacrolimus-Methotrexate RA Study Group.  Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: A six-month, open-label study.  Arthritis Rheum 2003; 48: 2763-2768.

Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA, on behalf of the Tacrolimus RA Study Group.  Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double-blind trial.  Arthritis Rheum  2003: 48: 3328-3337.

Peirce A, Lipsky P, Schwartz BD.  Mitigate risk and increase success of lupus clinical trials:  Design strategies from a Lupus Research Institute conference.  The Rheumatologist.  2010; 4(8):31-36.

Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri, M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, Smith A, Morgenroth LP, Arrieta A, Shimony M, Siener C, Jaros M, Shale P, McCall JM, Nagaraju K, van den Anker J, Conklin LS, Cnaan A, Gordish-Dressman H, Damsker JM, Clemens PR, and the Cooperative International Neuromuscular Research Group. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019; 93(13):e1312

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Mar T, Ryan MM, Webster R, Castro D, Finkel RS, Smith A, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathrout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet, A, Cornbish MR, Clemens PC.  Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018; 136:140–150.